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In vitro and in vivo evaluation of CHIBA-3007 as a novel radioligand for the 
glycine transporter 1 
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Glycine plays an important role in excitatory neurotransmission via 
strychnine-insensitive glycine sites located on the N-methyl-D-aspartate (NMDA) 
receptor (Figure 1). In the central nervous system (CNS), synaptic levels of glycine are 
regulated by specific sodium/chloride-dependent transporters. The actions of glycine are 
terminated by reuptake via two high-affinity glycine transporters referred to as glycine 
transporter 1 (GlyT-1) and glycine transporter 2 (GlyT-2). Two subtypes of glycine 
transporters, GlyT-1 and GlyT-2, have been identified, and we focused on GlyT-1. 
GlyT-1 is expressed at glutamatergic synapses throughout the mammalian brain and 
co-localizes with the NMDA receptor. Potentiation of NMDA receptor function by 
pharmacological manipulation may be a useful approach for treating diseases associated 
with NMDA receptor hypofunction such as schizophrenia. One possible strategy is to 
increase synaptic levels of glycine by blocking GlyT-1. However, no reports are 
available on the levels of GlyT-1 in postmortem brain samples from patients with 
schizophrenia. Therefore, it is of great interest not only to measure the dose–occupancy 
relationships of potential therapeutic GlyT-1 inhibitors but also to analyze pathological 
changes in GlyT-1 expression in the intact human brain using positron emission 
tomography (PET). Previously, two sarcosine-based GlyT-1 inhibitors [3H]NFPS, 
[3H](R)-NPTS , and some non-sarcosine-basedGlyT-1 inhibitors 
[3H]N-methyl-SSR504734 , [3H]SB-733993 and [3H]GSK931145, have been reported, 
and some reports have indicated that PET GlyT-1 radioligands entered an early clinical 
study. However, these radioligands may be less suitable radioligands for studying 
GlyT-1, Therefore, the challenge remains to identify suitable radioligands to study 
GlyT-1. 
3-Chloro-N-((S)-((R)-1-methylpiperidin-2-yl)(thiophen-3-yl)methyl)-4-(trifluoromethyl
)picolinamide (CHIBA-3007)(Figure 2), is a novel non-sarcosine-based GlyT-1 inhibitor. 
We found that CHIBA-3007 was a more potent GlyT-1 inhibitor than SSR504734 (this 
study). In the present study, we report the characterization of new radioligands 
[3H]CHIBA-3007 and [11C]CHIBA-3007, for studying GlyT-1 in the brain. 
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